Tango Therapeutics, Inc. (TNGX)

NGM – Real Time Price. Currency in USD

23.50

+0.02 (0.09%)

At close: May 12, 2026, 4:00 PM EDT

23.58

+0.08 (0.34%)

Pre-market: May 13, 2026, 7:36 AM EDT

04.05.2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a non-qualified stock option to purchase an aggregate of 240,000 shares of its common stock and 40,000 restricted stock units (RSUs) to Matthew Gall, the Company's Chief Financial Officer and (ii) a non-qualified stock option to purchase an aggregate of 199,650 shares of its common stock and 33,250 RSUs to a new employee, under Tango Therapeutics' 2023 Inducement Plan.

30.04.2026

Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results

Tango Therapeutics stock has soared this year on its pancreatic cancer treatment combination with Revolution Medicines.

15.04.2026

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

- Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership -

08.04.2026

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

27,000 common shares were sold via option exercise on April 1, 2026, generating proceeds of approximately $572,000 at a weighted average of $21.20 per share. The transaction reduced Adam's direct common stock position from 139,622 to 112,622 shares -- a reduction of 19.34% of her pre-sale holdings.

30.03.2026

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

Adam Crystal sold 20,251 shares for a transaction value of ~$304,000 on March 5, 2026, at an average price of around $15 per share. This sale represented 15.24% of Crystal's direct holdings, reducing his directly held position from 132,873 to 112,622 shares.

09.03.2026

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts.

06.03.2026

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Tango Therapeutics, Inc. is downgraded to Hold after a sharp rally, with 2026 positioned as a pivotal, data-driven year. Vopimetostat, the lead PRMT5 inhibitor, advances to a pivotal trial in 2L MTAP-deleted pancreatic cancer, with FDA-aligned design and robust enrollment. TNGX boasts a $343m cash position, partnerships with Gilead and Revolution Medicines, and multiple upcoming data catalysts, but faces fierce competition.

Videos

No Data

There is no data to display

Press releases

04.05.2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15.04.2026

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

- Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership -

08.01.2026

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a distinguished leader with extensive clinical development and leadership experience and who has served on the Tango Board of Directors since 2018, who will drive the next phase of company growth.

05.01.2026

Tango Therapeutics Appoints Sung Lee to Board of Directors

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries.

Tango Therapeutics, Inc. (TNGX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Videos

No Data

Press releases

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Tango Therapeutics Appoints Sung Lee to Board of Directors

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Videos

No Data

Press releases

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Tango Therapeutics Appoints Sung Lee to Board of Directors

Search stocks

Tango Therapeutics, Inc. (TNGX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Videos

No Data

Press releases

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Tango Therapeutics Appoints Sung Lee to Board of Directors

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Videos

No Data

Press releases

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Tango Therapeutics Appoints Sung Lee to Board of Directors